重度のうつ病患者の補助療法としてのルマテペロン: ランダム化,ダブルブラインド,フェーズ3試験の結果
Suresh Durgam1,2, Willie R Earley1, Susan G Kozauer1
1Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, New Jersey.
The Journal of clinical psychiatry
|August 28, 2025
まとめ
併用ルマテプロン42 mgは,抗うつ薬療法 (ADT) に不十分な反応を示したメジャーうつ病 (MDD) の患者で,うつ病の症状を有意に改善しました. 治療はよく耐えており,好ましい安全性プロファイルを示した.
科学分野:
- 精神科
- 神経科学
- 薬理学について
背景:
- 重度のうつ病 (MDD) は,特に標準的な抗うつ薬療法 (ADT) に不十分な反応を示した患者において,重大な課題となっています.
- この患者集団の満たされていないニーズに対処するために新しい治療戦略が必要です.
- ルマテペロンは新しい抗精神病薬で セロトニン,ドーパミン,グルタミン酸の神経伝達を調節します
研究 の 目的:
- MDDと不十分なADT応答を有する成人の患者における追加ルマテプロン42 mgの有効性と安全性を調査する.
- 鬱症状の重症度および全般的な疾患状態に対するルマテペロンの影響を評価する.
主な方法:
- MDDの成人 (18~65歳) を対象としたランダム化,ダブルブラインド,プラセボ対照試験.
- 参加者は1〜2回のADTに不十分な反応を示し,MADRS,CGI- S,QIDS- SR-16の特定のベースラインスコアを示した.
- 患者は6週間プラセボ (n=243) またはルマテペロン42 mg (n=242) を併用した.
主要な成果:
- プラセボ + ADTと比較して,ルマテプロン + ADTは,MADRS総スコア (LSMD = - 4. 9,P < . 0001) とCGI- Sスコア (LSMD = - 0. 7,P < . 0001) で統計的に有意な改善を示した.
- QIDS- SR-16で評価された患者の報告されたうつ病は,ルマテペロン+ADTで有意な改善を示した (LSMD= - 2. 4,P< .0001).
- 口の乾燥,疲労,震えなどの一般的な有害事象で,ルマテプロンは一般的によく耐えました. 体重増加や心代謝異常のリスクは最小で,自殺願望の出現は低かった.
結論:
- ADTに十分な反応を示していないMDD患者のうつ症状と疾患の重症度を改善する効果があります.
- ルマテペロンは,この患者集団で一般的によく耐える安全性プロファイルを示した.
- この発見は,ADT反応が不十分であるMDDの潜在的な治療法としてルマテペロンを支持しています.
関連する概念動画
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Depressive Disorders: MDD and Dysthymia
208
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
208
Antidepressant Drugs: Overview
741
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
741
Electroconvulsive Therapy
182
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
182
Mania and Antimanic Drugs: Overview
318
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
318
Drug Administration and Therapy Phases: Overview
738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738


